2021 George A. Uriano Award

The group is recognized for leadership in establishing the NIST Genome Editing Consortium to develop measurements and standards that increase confidence in genome-edited products, which offer a novel approach to treat and cure disease. The lack of common standards to assess whether a genome editing therapy is correctly editing its target gene has hindered commercialization of products. The consortium convenes key stakeholders, including competing entities, to address pre-competitive measurement challenges insurmountable by any one entity alone. With its novel model, the consortium strengthens ties between NIST and industry to accelerate the development and translation of life-saving genome editing technologies from the lab to the clinic.